Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Public ClinicalTrials.gov record NCT00005803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial
Study identification
- NCT ID
- NCT00005803
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Enrollment
- 76 participants
Conditions and interventions
Conditions
- Prolymphocytic Leukemia
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Childhood Hodgkin Lymphoma
- Recurrent Childhood Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Childhood Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma
- T-Cell Chronic Lymphocytic Leukemia
- T-Cell Prolymphocytic Leukemia
Interventions
- Autologous Hematopoietic Stem Cell Transplantation Procedure
- Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation Procedure
- Carmustine Drug
- Cyclophosphamide Drug
- Cyclosporine Drug
- Cytarabine Drug
- Etoposide Drug
- Fludarabine Phosphate Drug
- Laboratory Biomarker Analysis Other
- Melphalan Drug
- Mycophenolate Mofetil Drug
- Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Peripheral Blood Stem Cell Transplantation Procedure
- Therapeutic Autologous Lymphocytes Biological
- Total-Body Irradiation Radiation
Procedure · Drug · Other + 2 more
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 1999
- Primary completion
- Dec 31, 2015
- Completion
- Sep 30, 2018
- Last update posted
- Jan 28, 2020
1999 – 2018
United States locations
- U.S. sites
- 4
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | — |
| LDS Hospital | Salt Lake City | Utah | 84143 | — |
| VA Puget Sound Health Care System | Seattle | Washington | 98101 | — |
| Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00005803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2020 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00005803 live on ClinicalTrials.gov.